Cathie Wood's Most Revealing Week: $52 Million in Snowflake, 41,000 Shares of Eli Lilly, and a $100 Million Roku Exit That Says Everything About Where ARK Is Headed

In the world of institutional investing, most fund managers make their moves quietly, disclosing them weeks or months after the fact in regulatory filings. Cathie Wood is not most fund managers. ARK Invest discloses its daily trades — every purchase, every sale, every position change — the same day it makes them, on its website, for the world to see and analyse in real time. That transparency, which Wood designed deliberately as part of her open-source investment philosophy, means that every week of ARK trading is a public document of conviction. This week, that document was one of the most revealing ARK has published in months. In a span of two trading days — June 17 and June 18, 2026 — ARK simultaneously made its largest single bet on the AI data infrastructure boom in the form of a $52 million Snowflake position, added 41,000 shares of Eli Lilly to its biotech holdings, and executed the most decisive strategic exit in its recent history by dumping nearly $100 million in Roku stock in a single session. Together, these three moves constitute a thesis statement about where Wood believes the next phase of the technology-driven bull market is going — and which bets from the previous phase she is abandoning.

Who Is Cathie Wood and Why Do Her Trades Move Markets

To understand why a single day of ARK trading generates the volume of financial coverage it does, you need to understand what ARK Invest is and why its positions are tracked so closely.

Cathie Wood founded ARK Investment Management in 2014, after a long career at AllianceBernstein. From its founding, ARK positioned itself as the only firm in the asset management industry exclusively focused on disruptive innovation — defined as technologies that change the way the world works, that cut across multiple sectors simultaneously, and that are typically misunderstood or underestimated by mainstream Wall Street analysis. The firm's flagship fund, the ARK Innovation ETF (ARKK), became one of the most discussed investment vehicles in the world after returning 152% in 2020, driven largely by concentrated positions in Tesla, Zoom, and a handful of other pandemic-era winners.

The subsequent performance record has been considerably more contested. ARKK gave back most of those gains between 2021 and 2023 as rising interest rates punished the high-multiple growth stocks that define the fund's universe. A Morningstar analysis published in March 2025 found that from 2014 to 2024, ARKK destroyed approximately $7 billion in investor wealth on a dollar-weighted basis — the third largest wealth destruction figure among all mutual funds and ETFs tracked by Morningstar's analyst Amy Arnott. In the first quarter of 2026, ARKW ranked second among the worst-performing ETFs, and ARKK ranked fifth, according to Morningstar analyst Bella Albrecht. Over the five days through June 18, 2026, ARKK saw net outflows of approximately $770 million.

And yet ARK's daily trade disclosures are among the most read financial documents in the retail investing universe, precisely because Wood's conviction investing — buying deeply, selling specifically, and explaining her reasoning publicly — turns every trade into a signal about what she believes the next cycle of disruptive technology growth looks like. When ARK buys $52 million of Snowflake in a single session, and simultaneously dumps $100 million of Roku, it is not simply a portfolio rebalancing exercise. It is a public declaration about which technologies are winning the AI transition and which are not.

The $52 Million Snowflake Purchase: Betting on the AI Data Platform

The centrepiece of ARK's June 18 trading day was the purchase of 223,690 shares of Snowflake Inc. — ticker SNOW — across the ARKK and ARKW ETFs, at a closing price of $232.29 per share, amounting to $52,459,778 in total. It was ARK's single largest single-day purchase of Snowflake in recent months and its most significant individual trade of the June 18 session.

To understand why Wood made this bet at this specific moment, you have to understand what has happened to Snowflake in the three weeks preceding the purchase.

On May 28, 2026, Snowflake reported its fiscal first quarter results — the quarter ended April 30 — and delivered numbers that surpassed analyst expectations by a margin that surprised even bullish observers. Revenue for the quarter came in at $1.39 billion, up 33% year on year. Product revenue — the core measure of Snowflake's operational momentum — grew 34% to $1.33 billion. Remaining performance obligations, the forward-looking indicator that measures contracted future revenue, grew 38% to $9.21 billion. Adjusted earnings per share of $0.39 beat consensus estimates. The company added 616 net new customers in the quarter. Most tellingly, 46 customers crossed the $1 million annual spending threshold in the quarter, compared to 26 in the same period the prior year — nearly double the rate of high-value customer formation.

Also on May 28, Snowflake announced a $6 billion multi-year commitment to Amazon Web Services infrastructure — a signal of the company's confidence in its own growth trajectory and its deepening integration with the world's largest cloud computing provider.

The market's reaction was electric. Snowflake shares surged 36.48% on May 28 alone, the biggest single-day gain in the company's history. In the three weeks between that earnings day and ARK's June 18 purchase, the shares remained elevated, with the stock showing a 41.43% gain over the month. That context is critical: ARK was not buying Snowflake when it was down and beaten. It was buying Snowflake after it had already surged, on the conviction that the business transformation driving that surge is durable rather than temporary.

What Snowflake Actually Does and Why AI Changes Its Story

Snowflake is a cloud data and analytics company. It helps organisations store, process, and share large volumes of data across multiple cloud environments — a function that was already strategically important in the pre-AI era and has become foundationally important in the AI era. Every AI model requires data — clean, well-organised, accessible, and interconnected data. Snowflake is the platform through which an increasing number of enterprises are making their data AI-ready.

The specific product driving the acceleration is Cortex AI — Snowflake's suite of AI capabilities embedded directly into its data platform. Cortex allows organisations to build AI applications, run large language models, and execute machine learning workflows directly inside their Snowflake environment, without moving data to a separate AI platform. Snowflake's Chief Financial Officer Brian Robins described the adoption of Cortex Code, a code generation tool built on Cortex, as producing a step-function change in usage — meaning the growth is not incremental but categorical, representing a fundamentally different level of engagement from customers.

The May 28 earnings report also included the announcement of Snowflake's planned acquisition of Natoma Labs, an enterprise Model Context Protocol platform for AI agents — signed on May 24 and expected to close in June 2026 — adding agentic AI capabilities to the platform and positioning Snowflake to serve the next wave of enterprise AI deployment. In February 2026, Snowflake had already acquired Observe Inc., an AI-powered observability platform, for $595.8 million.

On TipRanks, Snowflake carries a Strong Buy consensus rating from 33 analysts, with three Hold ratings and no Sells. The average analyst price target of $299.06 implies approximately 28.7% upside from the June 18 purchase price. If that target is achieved, ARK's $52 million position would be worth approximately $67 million — a roughly $15 million gain from a single trade. Snowflake's own projections for its addressable market reach approximately $355 billion by 2029, as AI, analytics, and data-sharing workloads continue expanding across virtually every industry.

The broader software sector's reaction to Snowflake's May 28 earnings further validates the macro significance of the report. ServiceNow, Oracle, and Palantir all gained more than 6% in the immediate aftermath, as investors grew more confident that AI tools would enhance rather than replace the enterprise software platforms they had already adopted.

The Eli Lilly Purchase: 41,000 Shares and the GLP-1 Convergence Thesis

One day before the Snowflake purchase, on June 17, 2026, ARK made a separate move that has generated its own wave of analysis: the purchase of 41,000 shares of Eli Lilly and Company — ticker LLY — across the ARKG and ARKK ETFs, valued at approximately $9.4 million based on current pricing.

Eli Lilly is, in the conventional investment universe, a pharmaceutical company. It is not a disruptive technology company in the traditional sense that ARK defines its investment universe. But the framing that Wood has consistently applied to Eli Lilly is that it is a healthcare technology company in the most important sense: it has developed drug technologies — specifically GLP-1 receptor agonists including Mounjaro for type 2 diabetes and Zepbound for obesity — that represent the most significant breakthrough in chronic disease management in decades, and that have the potential to disrupt not just the pharmaceutical sector but the entire healthcare cost structure.

The investment case for Lilly in 2026 is underpinned by financial momentum that is difficult to argue with. The company delivered 56% revenue growth in the first quarter of 2026 and raised its full-year revenue guidance by $2 billion. Full-year 2026 guidance stands at $80 billion to $83 billion in revenue, with non-GAAP earnings per share of $33.50 to $35.00. In the first quarter alone, Lilly delivered on multiple strategic milestones: the FDA approved Foundayo — the brand name for orforglipron, the first oral GLP-1 pill that can be taken at any time of day without food or water restrictions — which Lilly characterised as a development that will meaningfully expand the number of people who can benefit from GLP-1s.

Beyond the commercial pipeline, Lilly has been actively expanding through acquisitions. In March 2026, it acquired Ventyx Biosciences for $1.1 billion net of cash, adding oral therapies for inflammatory-mediated diseases. Earlier, it acquired Verve Therapeutics for approximately $549 million net of cash plus contingent value rights, adding genetic medicines for cardiovascular disease. In a particularly significant government partnership, Lilly announced a Medicare GLP-1 Bridge program that will give Medicare beneficiaries access to discounted Lilly obesity medicines beginning July 1, 2026 through December 2027 — a programme that massively expands Lilly's addressable market and validates the political and regulatory environment for GLP-1 drugs.

ARK's addition of 8,487 shares through the ARKG and ARKK ETFs — with the separate 41,000 share figure representing the broader ARK Investment Management position — reflects a thesis that Lilly sits at the intersection of biotechnology and platform-scale healthcare disruption. Wood has previously described GLP-1 drugs as potentially the most significant contribution to public health since vaccines, arguing that their applications will extend well beyond obesity and diabetes into cardiovascular disease, liver disease, addiction treatment, and potentially cognitive health. If those extensions prove out clinically, Lilly's current revenue trajectory understates its long-term commercial potential by a significant margin.

The shares traded between $1,088.66 and $1,125.59 on June 20, 2026, with a 52-week range of $623.78 to $1,182.73 — meaning ARK's purchase came well off the all-time high but in a position of relative strength, consistent with the firm's pattern of buying on dips within established uptrends.

The $100 Million Roku Exit: The End of an Era

If the Snowflake purchase and the Eli Lilly additions represent ARK's convictions about where value is being created, the Roku selling spree in the same week represents an equally clear conviction about where value is not being preserved.

On June 18, 2026, ARK sold 721,279 Roku shares across its funds for approximately $99.6 million. This was the largest single-day Roku sale in ARK's history and followed a Wednesday sale of 239,267 shares and an earlier week sale of approximately $93.7 million worth of stock. In total, ARK's Roku liquidation this week ran to somewhere in the range of $280 million to $300 million in gross sales value — one of the most aggressive portfolio exits ARK has executed in recent memory.

The Roku exit carries particular symbolic weight in the context of ARK's history. ARK had been one of Roku's most prominent long-term bulls, once projecting the streaming platform could reach $605 per share by 2026. That target was never approached. Roku has faced persistent headwinds from advertising market softness, increasing competition in the connected TV operating system market, and most recently a strategic shift triggered by news that Fox Corporation is in discussions to acquire Roku — a deal that ARK apparently views as a signal to exit rather than hold.

The Fox acquisition context matters. When a company that ARK championed as an independent platform play becomes the subject of an acquisition by a legacy media company, it fundamentally changes the investment thesis. ARK's disruptive innovation framework does not typically value companies as acquisition targets at legacy media acquisition multiples. It values them as independent platform builders with exponentially expanding addressable markets. A Roku absorbed into Fox is not the Roku that ARK bought and held for years. It is a media asset, and media assets are not the kind of disruptive compounders that justify ARK-style position sizing.

The Full Picture: A Portfolio Rotating Toward AI Data Infrastructure and Healthcare Disruption

Stepping back from the individual trades, the full picture of ARK's June 17 to 18 activity describes a deliberate rotation that is consistent with Wood's stated views on the current market cycle.

She has been publicly arguing since June 5, 2026, that investors have been focusing on the wrong signals when assessing the outlook for inflation, interest rates, and stocks — that the deflationary pressure from technological disruption is being systematically underweighted by a market that remains anchored to historical frameworks that do not account for the speed of AI-driven productivity gains.

The portfolio rotation this week translates that argument into action. Snowflake represents AI data infrastructure — the picks-and-shovels play on the AI economy that benefits from every company's decision to build AI capabilities, regardless of which specific AI models or applications ultimately win. Eli Lilly represents healthcare technology disruption at the platform level — a drug technology so significant that it creates new markets rather than competing in existing ones. And the Roku exit represents the pruning of a legacy disruption thesis that has matured into something other than what it was.

ARK also bought shares of SpaceX through the SPCX IPO on its debut date of June 12, 2026, and added to its Coinbase position — two further data points confirming the same directional logic: space infrastructure, AI, crypto infrastructure, healthcare disruption, and cloud data platforms are where ARK's conviction is concentrating, while legacy tech-adjacent plays with constrained independence are being exited.

Whether Wood's timing proves correct — whether Snowflake's AI-driven acceleration is durable, whether Eli Lilly's GLP-1 franchise grows into its multiple, whether the broader portfolio rotation generates returns that justify the outflows ARK has been experiencing — is a question the market will answer over the coming quarters. What this week's trading has confirmed is that ARK's investment thesis is as distinctive and as conviction-driven as it has ever been. The firm is not hedging. It is not spreading bets for comfort. It is doubling down on the same core argument it has made since its founding: that exponential technologies create exponential value, and that the window to buy them before the mainstream catches up is never as long as it looks.

This article reflects publicly available trading data and analyst assessments and does not constitute investment advice. Past performance is not indicative of future results. Investors should conduct their own due diligence and consult a qualified financial adviser before making investment decisions.

Sources

TheStreet — Cathie Wood buys $52 million of surging tech stock (June 20, 2026): https://www.thestreet.com/investing/stocks/cathie-wood-buys-52-million-of-surging-tech-stock

Yahoo Finance — Cathie Wood buys $52 million of surging tech stock: https://finance.yahoo.com/markets/stocks/articles/cathie-wood-buys-52-million-210300507.html

Eciks.org — ARK Invest CEO snaps up $52 million in Snowflake shares, betting on AI-driven cloud data platform momentum: https://eciks.org/9995-23549-cathie-wood-snowflake-52-million-buy

GuruFocus — Eli Lilly (LLY) Sees Purchase of 41,000 Shares by ARK Investment (June 17, 2026): https://www.gurufocus.com/news/8921793/eli-lilly-lly-sees-purchase-of-41000-shares-by-ark-investment

TipRanks — Cathie Wood Buys $22M of Tesla, $52M of Snowflake, Continues Dumping Roku Shares: https://www.tipranks.com/news/cathie-wood-buys-22m-of-tesla-52m-of-snowflake-continues-dumping-roku-shares

Benzinga — Cathie Wood's Ark Invest Buys $22 Million In Tesla Stock As Elon Musk Exercises $110.55 Billion In Option: https://www.benzinga.com/etfs/broad-u-s-equity-etfs/26/06/53295583/cathie-woods-ark-invest-buys-22-million-in-tesla-stock-as-elon-musk-exercises-110-55-b

Investing.com — Cathie Wood's ARK sells Roku stock, buys Tesla and Snowflake: https://www.investing.com/news/company-news/cathie-woods-ark-sells-roku-stock-buys-tesla-and-snowflake-93CH-4751188

Seeking Alpha — Cathie Wood's ARK Invest buys TSLA & SNOW; exits $77M in Roku shares: https://seekingalpha.com/news/4605193-cathie-woods-ark-invest-buys-tsla-snow-exits-77m-in-roku-shares

SEC EDGAR — Snowflake Inc. Form 10-Q (FY2026, Quarter ended April 30, 2026): https://www.sec.gov/Archives/edgar/data/0001640147/000164014726000030/snow-20260430.htm

SEC EDGAR — Eli Lilly and Company Form 8-K, Q1 2026 Earnings (56% revenue growth): https://www.sec.gov/Archives/edgar/data/0000059478/000005947826000043/q126lillysalesandearningsp.htm

SEC EDGAR — Eli Lilly and Company Form 8-K, Q4 2025 Earnings and 2026 Guidance: https://www.sec.gov/Archives/edgar/data/0000059478/000005947826000008/q425lillysalesandearningsp.htm

SEC EDGAR — Eli Lilly and Company Form 10-Q (FY2026, Ventyx and Verve acquisitions): https://www.sec.gov/Archives/edgar/data/0000059478/000005947826000045/lly-20260331.htm